Primary Biliary Cirrhosis News and Research

RSS
Primary biliary cirrhosis is a chronic disease that causes the bile ducts in the liver to become inflamed and damaged and, ultimately, disappear. Bile is a liquid produced in the liver that travels through the bile ducts to the gallbladder and then the small intestine, where it helps digest fats and fat-soluble vitamins A, D, E, and K. When the bile ducts become damaged from chronic inflammation, bile builds up in the liver, injuring liver tissue.
EMA COMP issues positive opinion to Albireo for A4250

EMA COMP issues positive opinion to Albireo for A4250

Rituximab shows promise against primary biliary cirrhosis

Rituximab shows promise against primary biliary cirrhosis

Liver transplantations for NASH-Cirrhosis increase dramatically

Liver transplantations for NASH-Cirrhosis increase dramatically

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

Positive results from Intercept OCA Phase II trial in patients with PBC

Positive results from Intercept OCA Phase II trial in patients with PBC

DSP, Intercept enter license agreement for OCA

DSP, Intercept enter license agreement for OCA

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Study underscores need for monitoring vitamin D levels in all cirrhosis patients

Study underscores need for monitoring vitamin D levels in all cirrhosis patients

New study identifies 15 genetic regions underlying primary biliary cirrhosis

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

UDCA fails to improve overall histology in NASH patients: Study

UDCA fails to improve overall histology in NASH patients: Study

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

International study evaluates new class of drugs for treating primary biliary cirrhosis

International study evaluates new class of drugs for treating primary biliary cirrhosis

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Intercept Pharmaceuticals completes $25M Preferred Series B financing

Intercept Pharmaceuticals completes $25M Preferred Series B financing

Positive results from Phase II clinical trial of INT-747 announced

Positive results from Phase II clinical trial of INT-747 announced

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Study unveils detrimental effects of high-dose ursodeoxycholic acid on patients with PSC

Study unveils detrimental effects of high-dose ursodeoxycholic acid on patients with PSC